# OnCo record nct05822752 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct05822752/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct05822752", "NCT05822752" ;
  schema:name "Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Bu"@en ;
  schema:alternateName "LIVIGNO-1"@en ;
  schema:description "A phase 2 trial of Budigalimab, Livmoniplimab, Lenvatinib in hepatocellular carcinoma, run by AbbVie, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct05822752/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT05822752> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2023-09-21" ;
  onco:cancers <https://onco.cc/cancers/hcc/>, <https://onco.cc/cancers/hcc-advanced/> ;
  onco:drugs <https://onco.cc/drugs/budigalimab/>, <https://onco.cc/drugs/livmoniplimab/>, <https://onco.cc/drugs/lenvatinib/>, <https://onco.cc/drugs/sorafenib/> ;
  onco:companies <https://onco.cc/companies/abbvie/> .